{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 41,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM compared to other indications.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/29",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.42,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Incidence of EGFR extracellular domain (ECD) and splice variant mutants in EGFR amplified and non-amplified GBM",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ea78cd1-f303-40ab-9073-a0ba18fc9e51",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.48,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "*For illustrative purposes only and not a head-to-head comparison. Differences exist between trial designs and subject characteristics and caution should be exercised when comparing data across studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b14ab865-a791-4932-b36b-f594972ec088",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.02,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "TCGA Cell, 2013; GBM: glioblastoma; CNS: central nervous system; PFS: progression free survival; OS: overall survival",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c34a44a-5358-4a42-8355-b06bd28990a4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.48,
        "x": 0.48,
        "y": 0.22
      },
      "kind": "table",
      "text": "Therapy (brain penetration %), Clinical Trial Results: NSCLC/BrCa, Clinical Trial Results: GBM",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ec6906b-48a8-465b-8a47-0879a73d114f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Poor activity of legacy EGFRi in GBM due to minimal activity against GBM-specific EGFR alterations and poor CNS penetration",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25d357af-b572-4eeb-8d59-5882d8d73102",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "6accd05d-d70b-450a-98ac-720814160d33",
      "evidence": "The slide presents a clear problem statement about the limitations of current EGFR inhibitors in GBM treatment.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "Describing the potential benefits of Erasca's pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}